Supplementary Table 2. Diagnostic performance of the ADAPT, Agile 3+ score and other non-invasive fibrosis scores for identifying advanced fibrosis (F3-F4) in the derivation and validation cohort.

Score(s)	AUROC (95% CI)	Thresholds*	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	LR+	LR-
Derivation								
ADAPT	0.879 (0.825-0.933)	< 3.705	89.7	60.1	25.7	97.2	2.22	0.19
		> 4.930	72.7	89.8	52.5	95.5	7.10	0.30
Agile 4	0.826 (0.747-0.904)	< 0.087	90.9	45.6	20.6	97.0	1.67	0.20
		> 0.466	63.6	90.0	49.1	94.1	6.21	0.41
Agile 3+	0.805 (0.725-0.886)	< 0.007	89.6	35.3	17.6	95.2	1.37	0.32
		> 0.091	59.1	90.1	48.1	93.4	5.97	0.45
APRI	0.642 (0.550-0.734)	< 0.245	90.9	23.0	15.5	94.2	1.18	39.6
		> 0.865	22.7	90.1	26.3	88.2	2.30	0.86
FIB-4	0.732 (0.643-0.820)	< 0.585	90.9	20.8	15.2	93.7	1.15	0.44
		> 1.690	40.9	90.1	39.1	90.7	4.13	0.66
NFS	0.800 (0.723-0.877)	< 0.115	90.9	45.6	20.6	97.0	1.67	0.20
		> 2.025	56.8	90.1	47.2	93.1	5.74	0.48
BARD	0.709 (0.632-0.786)	> 2	75.0	55.1	20.6	93.4	1.67	0.45
Validation								
ADAPT	0.885 (0.772-0.998)	< 3.710	91.7	60.8	17.8	98.8	2.34	0.14
		> 4.945	66.7	94.6	53.3	96.9	12.4	0.35
Agile 3+	0.856 (0.671-1.000)	< 0.005	83.3	30.8	10.0	95.2	1.20	0.54
		> 0.105	83.3	93.1	52.6	98.4	12.0	0.18
Agile 4	0.855 (0.663-1.000)	< 0.045	83.3	24.6	10.3	94.1	1.11	0.68
		> 0.500	83.3	90.0	43.5	98.3	8.33	0.19

	AUROC (95% CI)	Threshold*	Sensitivity	Specificity	PPV	NPV	LR+	LR-
APRI	0.882 (0.780-0.984)	< 0.245	100.0	24.6	10.9	100.0	1.33	0.00
		> 0.870	58.3	88.5	31.8	95.8	5.06	0.47
FIB-4	0.878 (0.721-1.000)	< 0.595	91.7	31.5	11.0	97.6	1.34	26.4
		> 1.695	83.3	92.3	50.0	98.4	10.8	0.18
NFS	0.869 (0.702-1.000)	< 0.18	91.7	44.6	13.3	98.3	1.66	0.19
		> 2.09	83.3	93.1	52.6	98.4	12.0	0.18
BARD	0.751 (0.573-0.928)	> 2	58.3	83.9	25.0	95.6	3.61	0.50

Abbreviations: AUROC, area under the receiver-operating characteristic curve; CI, confidence interval; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, Fibrosis-4; NFS, NAFLD fibrosis score; NPV, negative predictive value; PPV, positive predictive value; LR+, likelihood ratio for positive results; LR- likelihood ratio for positive results.

*Thresholds were determined from the individual patient data study group as corresponding to 90% sensitivity (lower value) and 90% specificity (upper value).